Energenesis Biomedical CO.,LTD.
TAI: 6657.TW0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Taiwan Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Han-min Chen
- Employees
- 35
- Headquarters
- Taipei, Taiwan
- IPO year
- 2023
- Market cap
- NT$3.6B
- Website
- https://www.energenesis-biomedical.com
Loading 6657…
Loading profile data…Frequently asked questions about 6657
What does Energenesis Biomedical CO.,LTD. (6657.TW) do?
Energenesis Biomedical CO.,LTD. operates in the biomedicine industry in Taiwan. It provides ENERGI-F703, which is Phase II clinical trial for use in treatment of diabetic foot ulcers; ENERGI-F701, a topical tonic for the treatment of alopecia that is in Phase II clinical trial; ENERGI-F711, a burn cream; ENERGI-F702 to treat metabolic diseases;...
Where does 6657.TW trade?
Energenesis Biomedical CO.,LTD. (6657.TW) trades on the Taiwan Stock Exchange.
What sector is 6657.TW in?
Energenesis Biomedical CO.,LTD. (6657.TW) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Energenesis Biomedical CO.,LTD.?
Han-min Chen is the chief executive officer of Energenesis Biomedical CO.,LTD. (6657.TW).
Where is Energenesis Biomedical CO.,LTD. headquartered?
Energenesis Biomedical CO.,LTD. is headquartered in Taiwan.
Does 6657.TW pay a dividend?
Energenesis Biomedical CO.,LTD. (6657.TW) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 6657.TW go public?
Energenesis Biomedical CO.,LTD. (6657.TW) completed its initial public offering in 2023.